Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07136701) titled 'Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs' on Aug. 14.
Study Type: Observational
Primary Sponsor: Qilu Hospital of Shandong University
Condition:
Pancreatic Neuroendocine Neoplasms (pNETs)
Recruitment Status: Not recruiting
Date of First Enrollment: August 31, 2025
Target Sample Size: 600
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07136701
Published by HT Digital Content Services with permission from Health Daily Digest....